Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ad 101
2. Ad-101
3. Ad101 Cpd
4. Sch 350581
5. Sch 350581 Dihydrochloride
6. Sch-350581
7. Sch350581
1. Chembl113436
2. (2,4-dimethylpyridin-3-yl)(4-methyl-4-((s)-3-methyl-4-((s)-1-(4-(trifluoromethyl)phenyl)ethyl)piperazin-1-yl)piperidin-1-yl)methanone
3. 306293-36-7
4. Sch 350581
5. Schembl4453513
6. Ad101
7. Ad-101
8. Bdbm50104946
9. (2,4-dimethylpyridin-3-yl)-[4-methyl-4-[(3s)-3-methyl-4-[(1s)-1-[4-(trifluoromethyl)phenyl]ethyl]piperazin-1-yl]piperidin-1-yl]methanone
10. (2,4-dimethyl-3-pyridyl)-[4-methyl-4-[(3s)-3-methyl-4-[(1s)-1-[4-(trifluoromethyl)phenyl]ethyl]piperazin-1-yl]-1-piperidyl]methanone
11. (2,4-dimethyl-pyridin-3-yl)-(4-methyl-4-{(s)-3-methyl-4-[(s)-1-(4-trifluoromethyl-phenyl)-ethyl]-piperazin-1-yl}-piperidin-1-yl)-methanone
12. Piperazine, 4-[1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-methyl-4-piperidinyl]-2-methyl-1-[(1s)-1-[4-(trifluoromethyl)phenyl]ethyl]-, (2s)-
| Molecular Weight | 502.6 g/mol |
|---|---|
| Molecular Formula | C28H37F3N4O |
| XLogP3 | 4.9 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 4 |
| Exact Mass | 502.29194630 g/mol |
| Monoisotopic Mass | 502.29194630 g/mol |
| Topological Polar Surface Area | 39.7 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 746 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
CCR5 Receptor Antagonists
Compounds and drugs that inhibit or block the activity of CCR5 RECEPTORS. (See all compounds classified as CCR5 Receptor Antagonists.)
ABOUT THIS PAGE
A AD101 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of AD101, including repackagers and relabelers. The FDA regulates AD101 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. AD101 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A AD101 supplier is an individual or a company that provides AD101 active pharmaceutical ingredient (API) or AD101 finished formulations upon request. The AD101 suppliers may include AD101 API manufacturers, exporters, distributors and traders.
AD101 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of AD101 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right AD101 GMP manufacturer or AD101 GMP API supplier for your needs.
A AD101 CoA (Certificate of Analysis) is a formal document that attests to AD101's compliance with AD101 specifications and serves as a tool for batch-level quality control.
AD101 CoA mostly includes findings from lab analyses of a specific batch. For each AD101 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
AD101 may be tested according to a variety of international standards, such as European Pharmacopoeia (AD101 EP), AD101 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (AD101 USP).
LOOKING FOR A SUPPLIER?
